Evidence map›Paper›PMID 41727856›Full record

ArticleFrontiers in pediatrics2025

Case Report: Cystic fibrosis transmembrane conductance regulator gene heterozygous variation presenting with abdominal pain and hepatopancreatic lesions in a child.

Xiu Lu, Lidong Ning, Hong Zhen, Ming Liang, Yulan Han, Hongyan Wei, Lingdong Zeng, Lihong Wei, Liqin Tan

Abstract readCase Reports
In one paragraph

Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiu Lu *Department of Pediatrics, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Lidong Ning *Department of Neurosurgery, National Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.
Hong ZhenDepartment of Pediatrics, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Ming LiangDepartment of Pediatrics, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Yulan HanDepartment of Pediatrics, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Hongyan WeiDepartment of Pediatrics, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Lingdong ZengDepartment of Pediatrics, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Lihong WeiEmergency Department, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Liqin TanDepartment of Pediatrics, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, leading to multi-system involvement. Case report: A 4-year-old girl presented with a 2-day history of abdominal pain. Clinical manifestations included recurrent epigastric pain and vomiting. Physical examination revealed abdominal distension, mild periumbilical tenderness, and hepatomegaly (liver palpable 4 cm below the right costal margin). Laboratory tests showed elevated pancreatic enzymes: serum amylase 607 U/L, lipase 634 U/L, and pancreatic amylase 252 U/L (all >3 times the upper limit of normal). Abdominal ultrasound demonstrated diffuse hepatic lesions and uneven echogenicity in pancreatic parenchyma. Computed tomography revealed chronic liver disease changes, possible cirrhosis and a slightly enlarged spleen. Hepatobiliary histopathological biopsy indicated biliary obstruction. Whole-exome sequencing identified CFTR allele variants c.3139G > T (paternal source) and c.1409T > A (maternal source). Comparative analysis with the existing literature verified that the G > T mutation at chromosome 7 (chr7):117250723 was previously unreported. Treatment with octreotide, omeprazole, and pancreatic enzyme replacement therapy led to symptom resolution. At follow-up, her condition remained stable: height=109 cm (10th to 25th percentile), weight=18.8 kg (25th to 50th percentile) and stable condition. Conclusion: The clinical manifestations of CF are diverse, and digestive tract symptoms are common; therefore, early identification and diagnosis are required. As chr7: 117250723 G > T may be a pathogenic gene, long-term follow-up is needed.

Indexed as

childcystic fibrosiscystic fibrosis transmembrane conductance regulatorhepatopancreatic ampullapancreatitis

Identifiers

PMID41727856
PMCPMC12916658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.